Ethic Inc. Has $7.95 Million Stock Holdings in Becton, Dickinson and Company $BDX

Ethic Inc. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 40,970 shares of the medical instruments supplier’s stock after acquiring an additional 3,568 shares during the period. Ethic Inc.’s holdings in Becton, Dickinson and Company were worth $7,951,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Strengthening Families & Communities LLC increased its position in shares of Becton, Dickinson and Company by 2.4% in the 4th quarter. Strengthening Families & Communities LLC now owns 14,583 shares of the medical instruments supplier’s stock valued at $2,830,000 after buying an additional 339 shares in the last quarter. Violich Capital Management Inc. boosted its stake in Becton, Dickinson and Company by 2.3% in the 4th quarter. Violich Capital Management Inc. now owns 20,286 shares of the medical instruments supplier’s stock worth $3,937,000 after purchasing an additional 461 shares during the period. Generali Asset Management SPA SGR boosted its stake in shares of Becton, Dickinson and Company by 1.1% during the 4th quarter. Generali Asset Management SPA SGR now owns 11,483 shares of the medical instruments supplier’s stock worth $2,229,000 after buying an additional 128 shares during the last quarter. FSB Premier Wealth Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 42.1% during the 4th quarter. FSB Premier Wealth Management Inc. now owns 11,276 shares of the medical instruments supplier’s stock worth $2,188,000 after buying an additional 3,341 shares during the last quarter. Finally, MGO One Seven LLC boosted its stake in shares of Becton, Dickinson and Company by 3.1% during the 4th quarter. MGO One Seven LLC now owns 13,714 shares of the medical instruments supplier’s stock worth $2,661,000 after buying an additional 416 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BDX shares. Argus reduced their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 23rd. Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Seven investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $184.71.

Becton, Dickinson and Company Trading Down 2.6%

Shares of NYSE:BDX opened at $149.24 on Friday. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a market capitalization of $42.49 billion, a P/E ratio of 37.78, a price-to-earnings-growth ratio of 10.63 and a beta of 0.22. The company has a 50-day simple moving average of $158.49 and a 200 day simple moving average of $181.08. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.58 and a current ratio of 0.94.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.32%. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same period last year, the business posted $3.35 EPS. Becton, Dickinson and Company’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.59 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 1,102 shares of company stock valued at $198,909. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Evercore raised its price target on BDX from $180 to $190, signaling continued confidence in the company’s outlook. Evercore target increase
• Positive Sentiment: Wells Fargo lifted its price target to $161 from $157, suggesting modest upside from current levels. Wells Fargo target increase
• Positive Sentiment: The company’s earnings beat, revenue beat, and higher profit guidance are supporting the stock’s rebound after the report. BD second-quarter fiscal 2026 financial results
• Neutral Sentiment: BD also appointed Vitor Roque as chief financial officer, a management change that is not clearly positive or negative for the stock. BD appoints Vitor Roque CFO
• Neutral Sentiment: Stifel lowered its price target to $175 from $215, which is still above the current share price but reflects a more cautious view. Stifel target cut

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.